Cargando…

Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups

BACKGROUND: Bevacizumab has an important role in first-line treatment of metastatic colorectal cancer. However, clinical trials studying its effect have involved distinct chemotherapy regimens with divergent results. The aim of this meta-analysis is to gather current data and evaluate not only the e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Macedo, Ligia Traldi, da Costa Lima, Andre Bacellar, Sasse, Andre Deeke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3350458/ https://www.ncbi.nlm.nih.gov/pubmed/22414244 http://dx.doi.org/10.1186/1471-2407-12-89

Ejemplares similares

Addition of Bevacizumab to Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Lima, André Bacellar Costa, et al.
Publicado: (2011)

Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer
por: Carvalho, Adriana Camargo, et al.
Publicado: (2017)

Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials
por: Loupakis, Fotios, et al.
Publicado: (2010)

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
por: Yamamoto, Shun, et al.
Publicado: (2021)

The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer
por: Yin, Chenxi, et al.
Publicado: (2016)

First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
por: Zhou, Yu‐Wen, et al.
Publicado: (2021)

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
por: Bencsikova, Beatrix, et al.
Publicado: (2015)

Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials
por: Chen, Yan-xian, et al.
Publicado: (2014)

A Non-Interventional Multicenter Study of First-Line Bevacizumab in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer in Lebanon
por: Temraz, Sally, et al.
Publicado: (2022)

Immunotherapy combined with chemotherapy improved clinical outcomes over bevacizumab combined with chemotherapy as first‐line therapy in adenocarcinoma patients
por: Wang, Min, et al.
Publicado: (2022)

Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis
por: Bai, Long, et al.
Publicado: (2016)

Relapsed urachal carcinoma responding to first‐line chemotherapy with capecitabine‐oxaliplatin plus bevacizumab
por: Hatano, Akihiko, et al.
Publicado: (2023)

A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
por: Loupakis, Fotios, et al.
Publicado: (2015)

Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis
por: Koch, Christine, et al.
Publicado: (2017)

The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing Chemotherapy
por: Jiang, Chang, et al.
Publicado: (2017)

Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer
por: Elshenawy, Mahmoud A., et al.
Publicado: (2020)

Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort
por: Conic, Irena, et al.
Publicado: (2022)

A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
por: Kim, Youjin, et al.
Publicado: (2019)

Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer
por: Yang, Qiong, et al.
Publicado: (2015)

The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?
por: Kruse, Vibeke, et al.
Publicado: (2013)

Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
por: Li, Zhigui, et al.
Publicado: (2018)

The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials
por: Jang, Hyun Joo, et al.
Publicado: (2017)

Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma
por: Tate, Shinichi, et al.
Publicado: (2021)

The Impact of Bevacizumab and Chemotherapy on Quality of Life in Metastatic Colorectal Cancer Patients
por: Moisuc, Diana Cornelia, et al.
Publicado: (2023)

Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial
por: Okines, A, et al.
Publicado: (2009)

Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study
por: Díaz-Rubio, Eduardo, et al.
Publicado: (2012)

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
por: Takahashi, Shunji, et al.
Publicado: (2022)

Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer
por: Rosen, Virginia M., et al.
Publicado: (2017)

Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer
por: Komatsu, Yoshito, et al.
Publicado: (2015)

Safety and Feasibility of Additional Tumor Debulking to First‐Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer
por: Gootjes, Elske C., et al.
Publicado: (2020)

Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients
por: Nakayama, Izuma, et al.
Publicado: (2017)

Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab
por: Ortiz-Morales, M. José, et al.
Publicado: (2022)

Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer
por: Geva, Ravit, et al.
Publicado: (2013)

Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First‐Line Gastric Cancer and Elevated Plasma VEGF‐A
por: Han, K, et al.
Publicado: (2016)

Bevacizumab with preoperative chemotherapy versus preoperative chemotherapy alone for colorectal cancer liver metastases: a retrospective cohort study
por: Lu, Zhen-Hai, et al.
Publicado: (2016)

First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis
por: Liu, Tianshu, et al.
Publicado: (2022)

Is there a role for consolidative radiotherapy in the treatment of aggressive and localized Non-Hodgkin Lymphoma? A systematic review with meta-analysis
por: dos Santos, Lucas Vieira, et al.
Publicado: (2012)

Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab
por: Sagawa, Tamotsu, et al.
Publicado: (2020)

Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report
por: Wang, Musen, et al.
Publicado: (2021)

Androgenic suppression combined with radiotherapy for the treatment of prostate adenocarcinoma: a systematic review
por: Sasse, André D, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_u3cmdorarmdbc5dh25f2mdgi7n